GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spyre Therapeutics Inc (NAS:SYRE) » Definitions » Degree of Operating Leverage

SYRE (Spyre Therapeutics) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Spyre Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Spyre Therapeutics does not have enough data to calculate Degree of Operating Leverage.


Spyre Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Spyre Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spyre Therapeutics Degree of Operating Leverage Chart

Spyre Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.33 -0.83 -

Spyre Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.42 - - - -

Competitive Comparison of Spyre Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Spyre Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spyre Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Degree of Operating Leverage falls into.


;
;

Spyre Therapeutics Degree of Operating Leverage Calculation

Spyre Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -214.359 (Mar. 2025) / -157.532 (Mar. 2024) - 1 )/( 0 (Mar. 2025) / 0.688 (Mar. 2024) - 1 )
=0.3607/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Spyre Therapeutics  (NAS:SYRE) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Spyre Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Spyre Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Spyre Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Executives
Scott L Burrows officer: Chief Financial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Heidy King-jones officer: See Remarks C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Fairmount Healthcare Co-invest L.p. director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Peter Evan Harwin director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Cameron Turtle officer: Chief Operating Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Michael Thomas Henderson director 421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p. director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p. director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jeff Marc Goldberg director, officer: President and CEO C/O AKCEA THERAPEUTICS, 55 CAMBRIDGE PARKWAY, STE 100, CAMBRIDGE MA 02142
Linda L Neuman officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
James Paul Kastenmayer officer: Interim CEO & General Counsel ONE MEDIMMUNE WAY, FLOOR ONE, AREA TWO, GAITHERSBURG MD 20879
Hanley Jr. Michael Conick officer: Chief Commercial Officer C/O AEGLEA THERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746